Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis - 17/09/14
Abstract |
Background |
The impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown.
Objective |
We sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis.
Methods |
We conducted a cross-sectional study of patients with plaque psoriasis (N = 1153) and palmoplantar psoriasis (N = 66) currently receiving systemic or light treatment for psoriasis.
Results |
Patients with palmoplantar psoriasis were more likely to report Dermatology Life Quality Index scores that correspond to at least a moderate impact on QoL (odds ratio [OR] 2.08; 95% confidence interval [CI] 1.20-3.61); problems with mobility (OR 1.98; 95% CI 1.10-3.58), self-care (OR 3.12; 95% CI 1.24-7.86), and usual activities (OR 2.47; 95% CI 1.44-4.22) on the European Quality of Life-5 Dimensions questionnaire; and heavy topical prescription use of at least twice daily in the preceding week (OR 2.81; 95% CI 1.63-4.85) than those with plaque psoriasis.
Limitations |
Our assessment tools may not account for all dimensions of health-related QoL affected by palmoplantar disease, and these results may not be generalizable to patients with milder forms of psoriasis.
Conclusion |
Patients with palmoplantar psoriasis experience greater health-related QoL impairment and are more likely to report heavy use of topical prescriptions than those with moderate to severe plaque psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : epidemiology, health-related quality of life, palmoplantar psoriasis, patient-reported outcomes, plaque psoriasis, psoriasis
Abbreviations used : BSA, CI, DLQI, EQ-5D, HRQoL, OR, PGA, Qol
Plan
| This study was supported by grant RC1-AR058204 and K24-AR064310 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr Gelfand), Dermatology Foundation Career Development Award (Dr Takeshita), T32-AR07465 from the National Institutes of Health (Mr Shin), and an unrestricted grant from Eli Lilly. The sponsors had no role in the design and conduct of the study, in the collection and management of the data, or in the preparation of the manuscript. An author from Eli Lilly participated in data analysis and interpretation, manuscript review, and decision to submit the manuscript. None of the other sponsors participated in data analysis/interpretation, review, or decision to submit the manuscript. |
|
| Disclosure: Dr Callis Duffin was an investigator, consultant, and/or speaker for AbbVie, Amgen, ApoPharma, Bristol-Myers Squibb, Celgene, Eli Lilly, Genzyme, Incyte, Janssen Biotech, Novo Nordisk, Pfizer, and Wyeth, receiving honoraria and/or salary; served on the advisory board of Amgen; and received residency/fellowship program funding from AbbVie and Amgen. Dr Krueger served as a consultant for AbbVie, Amgen, and Janssen Biotech; had grants or has pending grants from AbbVie and Amgen; and received payment for lectures and travel-related expenses from AbbVie, Amgen, and Janssen Biotech. Dr Robertson is employed by the National Psoriasis Foundation, which receives unrestricted financial support from companies that make products used to treat psoriasis and psoriatic arthritis, including AbbVie, Amgen, Celgene, Eli Lilly, Galderma Laboratories LP, Janssen Biotech, Leo Pharma, Novartis, Pfizer, and Stiefel, a GSK company. Dr Robertson has also served as an uncompensated member of advisory boards at AbbVie and Merck. Dr Van Voorhees served on advisory boards for Amgen, AbbVie, Genentech, Warner Chilcott, Leo, and Janssen Biotech; served as an investigator for Amgen and AbbVie, receiving grants; and served as a consultant for Amgen. Ms Edson-Heredia is a full-time employee and stockholder of Eli Lilly. Dr Gelfand served as a consultant for AbbVie, Amgen, Eli Lilly, Merck, Janssen Biotech, Novartis, and Pfizer, receiving honoraria; had grants or has pending grants from AbbVie, Amgen, Genentech, Novartis, Eli Lilly, and Pfizer; and received payment for continuing medical education work related to psoriasis. Ms Chung, Drs Takeshita and Troxel, and Mr Shin have no conflicts of interest to declare. |
Vol 71 - N° 4
P. 623-632 - octobre 2014 Retour au numéro
Article précédent
- American Board of Dermatology Examination Dates
- Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting
- Junko Takeshita, Kristina Callis Duffin, Daniel B. Shin, Gerald G. Krueger, Andrew D. Robertson, Andrea B. Troxel, Abby S. Van Voorhees, Joel M. Gelfand
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?